Genome-wide copy number in 48 hours

Trying to get the complete copy number view from your FFPE samples but frustrated by the limitations of existing techniques?

Cancer researchers and clinicians are increasingly searching for a high-quality, whole-genome copy number solution for their degraded FFPE-derived tumor DNA to decipher the number and complexity of copy number aberrations across the genome. It has been established that these changes can be an important prognostic indicator as well as being critical to an understanding of the clonal evolution of a cancer.

The NEW OncoScan FFPE Assay Kit represents a breakthrough capability in solid tumor copy number analysis. Based on the novel Molecular Inversion Probe (MIP) technology, this new product offers:

  • Low sample input, fast results – from only 80 ng of FFPE-derived DNA to results in 48 hours
  • One assay, multiple views – whole-genome copy number, loss of heterozygosity (LOH), and key somatic mutations analysis
  • High-resolution copy number detection in ~900 cancer genes
  • Rapid analysis – from data to copy number calls for hundreds of samples in minutes using OncoScan Nexus Express Software

View key OncoScan FFPE assay publications by completing the form below.


"We performed testing of the new OncoScan® FFPE Assay Kit at ARUP and were able to detect FISH-confirmed aberrations in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting that OncoScan FFPE Assay Kit can be considered a viable, higher resolution and higher specificity alternative to FISH testing for confirmation of cancer gene aberrations in solid tumor tissue. Because OncoScan FFPE Assay Kit has whole-genome resolution, we also obtained valuable incremental copy number aberrations in these samples."

Sarah South, PhD, Medical Director, Cytogenetics, Genomic Microarray and Genetic Processing Laboratories, ARUP Laboratories

"We believe that the OncoScan assay is a robust platform for the rapid discovery and validation of novel prognostic copy number signatures that may also be useful in a clinical setting for the detection of specific gains in tumors as markers for patient stratification."

Professor Torsten Pietsch, MD, PhD, Institute of Neuropathology, University of Bonn, Germany